- The shares of Bristol-Myers Squibb Co (NYSE: BMY) have received an $81 price target from BMO Capital. These are the details.
The shares of Bristol-Myers Squibb Co (NYSE: BMY) have received an $81 price target from BMO Capital. And BMO Capital analyst Evan Seigerman increased the price target on Bristol-Myers from $74 while maintaining an “Outperform” rating on the shares.
Seigerman adjusted the rating as the company’s new safety and efficacy data for mavacamten from the VALOR-HCM trial at ACC improves the setup for sentiment regarding its PDUFA on April 28. And Seigerman pointed out that Bristol-Myers shares are undervalued given the company’s strong fundamentals.
Plus Seigerman believes that the company’s margin leverage is underestimated.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.